Provista Diagnostics Secures $6MM Series B Financing

New York, NY – April 16, 2014 – Provista Diagnostics, Inc., a privately held molecular diagnostics company developing and commercializing diagnostic, prognostic and predictive tests for cancers affecting women, today announced completion of its Series B financing.  The $6.0 million Series B financing was fulfilled by the company’s existing investors.

This funding will enable the company to expand the commercial market development for dtectDx™ Breast, as well as pursue additional clinical trials as the company works toward 510K regulatory clearances for the assay.

“We are grateful to our shareholders for their continuing support of the company and its vision, especially now, as we navigate through this important period,” said David Reese, PhD, President and CEO.  “We have made great progress over the past two years, and this investment reflects the continued belief in our science and technology innovations.”

To date, Provista Diagnostics has raised $19.5 million, including the current Series B financing and $13.5 million through Series A financings in 2012 and 2013.

About Provista                                                               

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###